Annexon to Present ARCHER II Baseline Characteristics at Retina Society; Topline Still on Track for Q4 2026

What happened

Annexon announced two oral presentations on vonaprument at the Retina Society 59th Annual Scientific Meeting, highlighting patient baseline characteristics from the Phase 3 ARCHER II trial in geographic atrophy (GA). The presentations emphasize Phase 2 vision protection results and suggest the enrolled Phase 3 population is well-matched to that earlier successful cohort, positioning the trial to replicate those outcomes. ARCHER II is described as the first pivotal trial designed to demonstrate protection of vision in GA, with Month 15 results now guided to the fourth quarter of 2026, a narrowing of the prior H2 2026 window. No new efficacy or safety data from the ongoing trial were disclosed; this is an interim scientific communication aimed at reinforcing confidence in the trial design. The announcement serves as a reminder of the near-term catalyst but does not alter the fundamental investment case.

Implication

Investors should treat this as a validation of the trial's scientific rationale without new clinical evidence, leaving the risk/reward unchanged. The emphasis on baseline consistency with Phase 2 is encouraging but the definitive test will be the Phase 3 efficacy and safety data. Annexon's cash runway into late Q1 2027 comfortably covers the readout, reducing immediate financing risk, though further dilution remains possible if timelines slip. A positive ARCHER II outcome would diversify revenue potential beyond GBS and likely trigger a re-rating; a miss would concentrate value on tanruprubart and pressure the stock. Maintain a BUY rating with close monitoring of the ARCHER II topline and any updates on the tanruprubart BLA submission.

Thesis delta

No material shift: the news reaffirms the existing thesis that Annexon has a late-stage GA program with a near-term catalyst. The company's emphasis on baseline consistency and Phase 2 vision protection maintains the probability of success, but the market will require positive Phase 3 data to re-rate. The master report's BUY rating and risk/reward view remain unchanged.